It appears possible to predict renal cell carcinoma (RCC) progression and death using readily available clinical and pathologic features, researchers concluded after conducting a retrospective cohort review involving >3,600 individuals. Participants had clear cell RCC (ccRCC; n=2,726), papillary RCC (papRCC; n=607), or chromophobe RCC (chrRCC; n=222). Investigators developed models based on clinicopathologic features to predict oncologic outcomes. Among the results:
- Progression-free survival c-index was 0.83 for ccRCC, 0.77 for papRCC, and 0.78 for chrRCC.
- Cancer-specific survival c-indexes were 0.86 for ccRCC and 0.83 for papRCC.
- Due to only 22 deaths from RCC, cancer-specific survival was not assessed for chrRCC.
Leibovich B, Lohse C, Cheville J, et al. Predicting oncologic outcomes in renal cell carcinoma after surgery. [Published online ahead of print February 2, 2018]. Eur Urol. doi:10.1016/j.eururo.2018.01.005.
This Week's Must Reads
Must Reads in Renal Cell Carcinoma
First-line avelumab/axitinib for RCC benefits wide range of patients, Choueiri TK et al. GUCS 2019, Abstract 544.